NVAX
The quarter: more science fair than victory lap
Novavax’s second quarter looked a lot like the kind of update investors have learned to hear with one eyebrow raised: revenue came in at $57 million, and the company logged a net loss of $53 million. Not exactly the kind of numbers that make the stock want to do cartwheels.
The good news? The partnership machine is still humming
The brighter part of the story is Novavax’s Sanofi partnership. The company says it’s making progress there, which matters because Novavax is no longer just selling a vaccine dream on vibes and a cool-sounding adjuvant platform. It needs actual commercial traction, and partnerships are the closest thing biotech has to a cheat code.
Why investors care
Novavax keeps pitching Matrix-M as a key piece of its future — a platform with room to expand beyond one product or one season. That’s the whole game here: can Novavax turn a one-product narrative into a broader platform story before the cash burn and losses keep stealing the spotlight?
If you own the stock, the key question isn’t whether the science sounds good. It’s whether the business can start acting like the science sounds good.
Big picture: Novavax still has a believable long-term story, but this quarter reminded everyone that believable and profitable are two very different sports.